Showing posts with label types of skin cancer. Show all posts
Showing posts with label types of skin cancer. Show all posts

Tuesday, July 16, 2013

A personal journey offers an intimate view of aging issues, skin cancerand facial reconstruction

[caption id="attachment_13545" align="alignleft" width="454"]Squamous cell skin cancer - wikimedia commons Squamous cell skin cancer - wikimedia commons[/caption]

Carol Forsloff---The nose is a high risk place for skin cancer.  From childhood on, almost every year mine turned red, even after moments in the sun.  Growing up in Oregon in the early 1940’s and 50’s, people had not heard of sunscreen, and instead used coconut oil to allow the skin to tan as opposed to burn.  Here is my personal experience of the consequences many people have as they face aging issues, skin cancer and reconstruction.

My nose never tanned, and the result of sunburns in my early years became dramatically painful after I turned 60.  That's because those sunburns had become small sores diagnosed as skin cancer, requiring surgeries

I had two Moh’s surgeries on my nose, one after I turned 60, in 2001 and another six years later.  But it was when I had a more aggressive cancer on my nose in 2013 that I learned how important it is to prevent sunburns and to take precautions in one’s early years.  So it is with this admonition,  on how to care for yourself I have done this video, that sunscreen and a hat are critical essentials from childhood to the grave, even on those colder days when the sun’s rays don’t look obvious.

Skin grafts and nose surgery are procedures that according to historians go back thousands of years, with sometimes strange results, as doctors tried everything from using the buttocks of slaves to places on the arm and other parts of the body to cover wounds after cancer sores were removed.  But it wasn’t until the 20th century these procedures were refined, so that surgeons now use  nasal reconstruction using a paramedial forehead flap.

The details of the process are on the Internet on both medical sites, such as Medscape, and YouTube where a few individuals have shared their personal experiences with this surgery.  Suffice to say, it is debilitating and disfiguring and requires many weeks of recovery at various stages.  It is one of those operations we might define as potentially painful and difficult.  Yet when the surgery is done well, as it usually is, the result can be dramatically favorable.

Still the surgeon’s hand needs help, and that’s what this video is all about.  It is done with major gratitude to Dr. Dieter F.  Hoffman of Kaiser in Portland, Oregon, whose surgical artistry provides the foundation for that gruesome to glamorous journey, for it will take additional time to heal wounds from a surgery that took place just 10 weeks ago.  But I can do it, and others can as well.  Those of you who facr skin changes in your later years can also benefit from this information.  At the same time, anyone who finds a sore that does not heal anywhere should see a dermatologist for an evaluation for the possibility of skin cancer.


Wednesday, June 16, 2010

Drug used to treat ALS found helpful in treatment of melanoma



 

[caption id="attachment_13545" align="alignleft" width="300" caption="skin cancer - wikimedia commons"][/caption]

The drug ordinarily used to treat Lou Gehrig's disease (ALS) has been found to show promise in the treatment of melanoma cells, the most serious type of skin cancer.

Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise using a drug called riluzole which they have learned decreases the action of Gm1, a receptor that is normally produced in the central nervous system that when activated on the surface of melanoma cells increases the growth and spread of the disease. 

James S. Goydos, MD, director of the Melanoma and Soft Tissue Oncology Program at CINJ and associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School, is the study’s senior author. declares, “We previously demonstrated that we could block the signals produced by Grm1 in melanoma cells. Now we have linked blocking of the signal with a decrease in growth, migration, and spread of melanoma, a critical step in validating Grm1 as a target for treating patients with melanoma. Because it is present in more than 60 percent of human melanomas, we have an appropriate ‘bull’s eye’ in Grm1, and riluzole is proving to be an effective arrow."

Dr. Goydos observed using new combinations of therapies that target multiple pathways involving riluzole would be helpful in the treatment of melanoma, based on these current studies.